IDH2 and acute myeloid leukemia: In patients with IDH1 mutation, ivosidenib in combination with HMA improved median overall survival as well as event free survival and response rates compared to monotherapy with HMA [35] while IDH-mutated AML patients who were considered too frail for HMA-based treatment may be offered monotherapy with IDH1/IDH2 inhibitors [17, 36].